2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Treatment Considerations, Supportive Care, Non-Biological Therapies, Pharmacology, Women’s Health, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3061 An old disease returns: Review of literature on vitamin k deficiency bleeding in infants

Ahmad Al-Huniti, MD, Heba Abdallah, MS2, Alexia Kessler3, Annelise Carlson4, Melanie Klemond, MD5, Anand Srinivasan, MBBS6, Anjali Sharathkumar, MD, MS7
1 Mayo Clinic, Rochester, Minnesota, United States
2 University of Florida, Gainesville, Florida, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Vanke Meisha Academy, Shenzhen, China
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 University of Iowa Health Care Stead Family Children's Hospital, Iowa City, Iowa, United States

Background:
Vitamin K deficiency bleeding (VKDB) is largely preventable with intramuscular vitamin K at birth, yet parental refusal of vitamin K prophylaxis is increasing in high-income countries. Consequently, prevalence of VKDB is rising. Because VKDB in newborns had become relatively rare in recent past, clinicians have limited experience recognizing it, potentially leading to delay in diagnosis and treatment and resulting in adverse clinical outcomes. We systematically reviewed the published literature to characterize the epidemiology of VKDB with emphasis on both common and rare bleeding symptoms, treatment and outcomes.

Methods:
A medical librarian conducted a comprehensive search of multiple electronic databases from inception through January 5, 2026 limited to English language and used the following MeSH terms: vitamin K deficiency bleeding, infant, vitamin K, prothrombin, blood, and hemostatic agents.

Two reviewers independently screened records and extracted individual case-level data; discrepancies were resolved by consensus. VKDB was diagnosed based on laboratory findings (PT, INR, aPTT, and PIVKA-II) and/or when the article explicitly stated that patients met diagnostic criteria for VKDB.  Based on the timing of presentation at birth, vitamin K deficiency was classified as early (< 24-hours), classic (2 days to 1 week) or late (1 week to 6 months) according to American Academy of Pediatrics recommendations. Denominators reflect cases with data available for that variable and are reported throughout. Predictors of mortality were evaluated using logistic regression analyses.

Results:
Of 726 unique records, 181 studies met inclusion criteria, contributing 2,332 VKDB cases from 33 countries: Japan (605/2,332, 25.9%), Turkey (334/2,332, 14.3%), Vietnam (233/2,332, 10.0%). Median age was 30 days (range 0-210 days); 67% were male. Exclusive breastfeeding was reported in 94.4% (1,605/1,701). Among 1,777 with Vitamin K prophylaxis data, 72.5% (1,289) received no vitamin K prophylaxis, either because prophylaxis was not offered and or because caregivers declined. Among 2,257 patients with reported VKDB type, late VKDB was the predominant subtype in 82.1 %(1,852/2,257), followed by classic in 9.3% (215/2,257) and early VKDB in 2.7% (60/2,257).

 

VKDB manifested with a broad spectrum of hemorrhagic presentations. Among infants with reported bleeding site, intracranial hemorrhage (ICH) was the most common bleeding manifestation in 73.8% (1,401/1,899), followed by gastrointestinal bleeding in 64.5% (316/490), mucosal bleeding in 63.8% (88/138), venipuncture-site bleeding (149/305, 48.9%), ecchymoses/skin bleeding (315/701, 44.9%), umbilical cord bleeding (105/275, 38.2%), genitourinary bleeding (21/71, 29.6%), intramuscular bleeding (10/51, 19.6%), and circumcision-site bleeding (8/136, 5.9%). Rare bleeding sites included retrobulbar (n=4) and vitreous (n=2), retinal (n=2), pulmonary (2), hemothorax (n=15), pericardial hemorrhage with cardiac tamponade (n=2), hemoperitoneum (n=4), adrenal (n=1), thymic (n=5), hemiscrotal bleeding (n=2), cephalohematoma (7), subaponeurotic (9), and subgaleal (n=4).

 

Among infants with available treatment data, vitamin K was administered in 1,911/1,918 (99.6%), fresh frozen plasma in 282/405 (69.6%), packed red blood cell transfusions in 136/208 (65.4%), and surgical intervention in 152/480 (31.7%). Prothrombin complex concentrate and recombinant factor VIIa were reported in a small number of cases (<10) with most studies did not report their use.

 

Survival data were available for 2,025 of 2,332 (86.83%) infants; overall mortality was 17.9% (363/2,025). ICH was a strong predictor of mortality (OR 10, 95% CI 4–25). Among infants with neurologic follow-up (0-48 months), 55.9% (461/825) experienced neurologic sequelae, most commonly motor deficits, seizure disorders, developmental delay, and hydrocephalus.

 

Conclusions:
VKDB is a life-threatening but largely preventable disorder that predominantly affects exclusively breastfed infants who have not received vitamin K prophylaxis. ICH is the most common presentation and is associated with 10-folds increase in mortality risk and long-term neurologic morbidity. VKDB should be considered in any infant younger than  six months presenting with unexplained bleeding, and vitamin K administration should be considered while coagulation studies are pending. Comprehensive counselling should be provided to families who decline neonatal vitamin K administration.

Ahmad Al-Huniti, MD: No relevant conflicts of interest to declare.